This study is conducted globally. The aim of this study is to describe the treatment
modalities and outcomes of bleeding episodes, surgery and prophylaxis in patients with factor
VII (FVII) deficiency in addition to evaluate the presence (in already treated patients)
and/or the appearance of inhibiting antibodies to FVII and/or therapy-related thrombosis.
Due to a Novo Nordisk commitment to the Committee for Medicinal Products for Human Use
(CHMP), Novo Nordisk receives data on treatment with activated recombinant human FVII
(rFVIIa, NovoSeven®) in patients with FVII deficiency from the Seven Treatment Evaluation
Registry (STER, NCT01269138). These patients can also have been treated with other
haemostatics for systemic administration.